When Does Wegovy Start Working? A Week-by-Week Timeline of Appetite, Side Effects, and Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• Wegovy starts working within hours of the first injection at the receptor level, but appetite suppression usually becomes noticeable in the first 1 to 2 weeks.
• Measurable weight loss typically begins between weeks 2 and 4. Average loss in STEP 1 was about 6% of body weight at 16 weeks (Wilding et al., NEJM 2021).
• The full 2.4 mg maintenance dose is reached at week 17 under the standard escalation schedule.
• Peak weight loss in trials was about 14.9% of body weight at 68 weeks. About 32% of patients lost at least 20%.
• Slower-than-expected progress in the first 4 weeks is common and not a sign of non-response. The 16-week mark is the standard early checkpoint.

Direct answer (40-60 words)

Wegovy starts working immediately at the receptor level, but most patients notice appetite suppression by week 1 or 2 and measurable weight loss by week 4. Following the standard dose escalation, the full 2.4 mg maintenance dose is reached at week 17. Average weight loss in the STEP 1 trial was 14.9% at 68 weeks.

Table of contents

1. The 30-second answer
2. Pharmacology: why Wegovy starts working immediately but takes weeks to show
3. Week-by-week timeline of effects
4. The standard 17-week dose escalation
5. Average weight loss in clinical trials by week
6. Appetite suppression timeline (different from weight loss)
7. Why some patients respond faster than others
8. The 16-week early checkpoint
9. When to talk to your provider
10. FAQ

Pharmacology: why Wegovy starts working immediately but takes weeks to show

Wegovy is the brand name for semaglutide 2.4 mg, a GLP-1 receptor agonist. The drug binds GLP-1 receptors in the gut, pancreas, and brain. Activation triggers four effects:

1. Slower gastric emptying (food sits in the stomach longer)
2. Increased glucose-dependent insulin secretion
3. Decreased glucagon release
4. Reduced appetite signaling in the hypothalamus and brainstem

The receptor activation happens within hours of injection. The drug reaches peak plasma concentration at about 1 to 3 days after a single dose. Half-life is approximately 165 hours, which is why it can be dosed once weekly.

But weight loss is a downstream consequence of behavior change. Patients eat less because they feel full faster and crave food less, then their bodies pull from fat stores. That process takes weeks to show on a scale. The receptor effect happens in hours, the visible result happens in weeks.

This gap is the source of most of the early-stage frustration with Wegovy. Patients hear "it works" and expect immediate scale changes. The actual experience is: appetite shifts in week 1 or 2, scale starts moving in week 3 or 4, and meaningful weight loss accumulates over months.

Week-by-week timeline of effects

Every patient is different, but the population data follows a predictable pattern.

Week 1 (0.25 mg starting dose):

• First injection on day 0
• Mild nausea or constipation possible within 24 to 48 hours
• Some patients notice slight reduction in appetite by day 3 to 5
• Most patients have not lost weight yet
• A small fraction lose 1 to 2 lbs from reduced food intake

Week 2 (0.25 mg, second injection):

• Second injection
• Appetite suppression starts to become more clearly noticeable
• "Food noise" (intrusive thoughts about food) often quiets
• Some weight loss showing on the scale, often 1 to 3 lbs

Week 3 (0.25 mg, third injection):

• Steady-state drug levels approaching
• Many patients describe feeling full faster during meals
• Mild GI symptoms common (nausea, constipation, reflux)
• Weight loss continues at roughly 1% of body weight per week for many patients

Week 4 (0.25 mg, fourth injection):

• End of the 0.25 mg titration phase
• Average weight loss to date: roughly 2 to 4 lbs
• Most patients moving to 0.5 mg the following week

Weeks 5-8 (0.5 mg):

• Dose increase, mild return of GI symptoms for 7 to 14 days
• Appetite suppression deepens
• Average loss by week 8: about 4 to 6% of starting body weight in STEP 1

Weeks 9-12 (1.0 mg):

• Another dose step, brief side-effect window
• Many patients notice a more meaningful change in body composition
• Average loss by week 12: about 6 to 8% of starting body weight

Weeks 13-16 (1.7 mg):

• The next-to-last titration step
• Some patients pause here longer if side effects are intense
• Average loss by week 16: about 8 to 10% of starting body weight

Week 17+ (2.4 mg maintenance):

• Full maintenance dose reached
• Maximum appetite suppression effect
• Continued steady weight loss for most patients
• Plateau possible around month 9 to 12

The standard 17-week dose escalation

The FDA-approved Wegovy dose escalation schedule:

Weeks	Weekly dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

The escalation is designed to reduce GI side effects. Starting directly at 2.4 mg would cause severe nausea and vomiting in most patients. Each step is held for 4 weeks to let the body adapt before the next increase.

Some patients tolerate slower titrations. If GI side effects are intense at 0.5 mg, your provider may extend that step to 6 or 8 weeks. The label allows flexibility. The 17-week schedule is the default, not the only path.

Average weight loss in clinical trials by week

The STEP 1 trial (Wilding et al., NEJM 2021) is the foundational efficacy study. It enrolled 1,961 adults with BMI 30+ (or 27+ with at least one weight-related comorbidity) and randomized them to semaglutide 2.4 mg or placebo. Both arms received lifestyle intervention.

Mean percent body weight change from baseline:

Week	Semaglutide arm	Placebo arm
4	-2.0%	-0.4%
8	-4.5%	-0.7%
12	-6.6%	-1.0%
16	-8.5%	-1.4%
28	-11.6%	-2.0%
44	-14.0%	-2.3%
68 (endpoint)	-14.9%	-2.4%

Roughly half the total weight loss happened in the first 16 weeks before the maintenance dose was reached. The other half came over the following year on the 2.4 mg maintenance dose.

Some patients responded faster (top quartile: 18 to 25% loss). Some responded slower (bottom quartile: 4 to 8% loss). The bottom 13% lost less than 5% of body weight at 68 weeks and were considered non-responders.

Appetite suppression timeline (different from weight loss)

Patients often ask about two different timelines that get confused.

Timeline 1: When does Wegovy start suppressing appetite?

• Day 0 to 3: receptor binding, drug accumulating
• Day 3 to 7: subtle appetite shift, smaller portions feel filling
• Week 2: clearer reduction in food noise
• Week 4 to 6: appetite suppression at the 0.25 mg dose roughly equal to a 25 to 35% caloric deficit for many patients
• Week 17+: maximum suppression at 2.4 mg

Timeline 2: When does Wegovy show weight loss on the scale?

• Week 1: minimal change for most
• Week 2 to 3: 1 to 3 lbs lost
• Week 4: average 2% of body weight lost
• Week 16: average 8.5% of body weight lost
• Week 68: average 14.9% of body weight lost

The two timelines are linked but not identical. Some patients experience strong appetite suppression but slower weight loss because they were not eating much above maintenance to begin with. Others see big scale changes early because their starting deficit was large.

Why some patients respond faster than others

Five factors explain most of the variation in response speed.

1. Starting BMI. Higher starting BMI typically means faster initial scale movement (more absolute weight to lose). The percent loss tends to converge over time.
2. Diet quality. Patients who pair Wegovy with a protein-anchored diet (100+ grams protein daily) lose visceral fat faster.
3. Activity level. Resistance training during weight loss preserves lean mass and supports faster fat loss.
4. Hydration. Patients often see misleading scale fluctuations if hydration drops by 2 to 3 lbs of water weight in week 1.
5. Baseline insulin sensitivity. Patients with insulin resistance or pre-diabetes sometimes lose weight slower at first, then accelerate as insulin levels normalize.

If your scale has not moved by week 4 to 6, the most common reason is not "Wegovy is not working." It is usually a combination of water-weight noise, eating slightly above the new maintenance, or measurement timing variability.

The 16-week early checkpoint

Most weight-loss specialists use 16 weeks as the early efficacy checkpoint. By week 16, you should be at the 1.7 mg dose and have lost a meaningful amount of weight.

The standard rule of thumb: at least 5% of body weight lost by week 16 indicates a responder. Less than 5% suggests a slower response that may benefit from additional support (dietitian referral, exercise prescription, or in some cases switching to tirzepatide).

The Wegovy label explicitly states that patients who have not lost at least 5% of body weight after 16 weeks at the maintenance dose should be reassessed. In practice, providers often use the 16-week mark even before reaching maintenance.

This is also the point where insurance plans often request progress documentation for prior authorization renewal. Tracking starting weight and weighing weekly under consistent conditions (same time, same scale, similar hydration state) gives you the data you need.

When to talk to your provider

During the first 4 weeks:

• Severe nausea or vomiting that prevents adequate hydration or nutrition
• Pancreatitis warning signs (severe upper abdominal pain radiating to back)
• Gallbladder symptoms (right-upper-quadrant pain after fatty meals)
• Any allergic reaction (rash, swelling, breathing difficulty)

Between weeks 4 and 16:

• No appetite reduction at all by week 4
• No weight change by week 6 to 8
• Worsening rather than improving GI symptoms past week 6
• New mood changes including persistent low mood

After week 16:

• Less than 5% body weight loss at the 1.7 mg or 2.4 mg dose
• Plateau lasting more than 8 weeks despite consistent diet
• Any new symptoms unrelated to GI side effects

The most common misconception is that Wegovy is "not working" at week 4 or 6. By those benchmarks, the drug has barely reached the active dose range. The honest assessment window is week 16, not week 4.

FAQ

How quickly does Wegovy start working? Wegovy binds receptors within hours of the first injection. Appetite suppression typically becomes noticeable in week 1 or 2. Measurable weight loss usually starts by week 3 or 4. The full clinical effect is reached after the 17-week titration to the 2.4 mg maintenance dose.

Will I lose weight in the first week of Wegovy? A small minority of patients lose 1 to 3 lbs in week 1, often from reduced food intake plus mild fluid shifts. Most patients see little change in week 1. The 0.25 mg starting dose is intentionally low to limit side effects, not to drive maximum weight loss.

Why have I not lost weight after 4 weeks on Wegovy? The most common reasons are: you are still on the 0.25 mg starting dose, water weight is masking fat loss, or you are eating closer to your new maintenance level than you realize. By week 4 the average loss is around 2% of body weight, which is 4 lbs for a 200 lb starting weight. Some patients fall below average.

When should I expect to see a scale change? Most patients see a scale change between week 2 and week 4. The change accelerates between week 8 and week 28, when the dose is increasing toward maintenance. Plateau periods of 1 to 3 weeks within the longer trend are normal.

How long until I reach the full Wegovy dose? The standard escalation reaches the 2.4 mg maintenance dose at week 17. Some patients spend extra time at 1.0 mg or 1.7 mg if side effects require it. Faster escalation than the 17-week schedule is rarely tolerated.

Can I lose weight on the 0.25 mg starting dose alone? Yes, modestly. The STEP 1 trial showed an average 2% body weight loss at week 4 (still on 0.25 mg). The starting dose suppresses appetite enough to drive a small calorie deficit for most patients but is not the dose that produces the full effect.

What if Wegovy is not working for me at week 16? Talk with your provider. Less than 5% body weight loss at 16 weeks of treatment (especially after 4+ weeks at the 1.7 mg or 2.4 mg dose) indicates a slower response. Options include extending titration, adding behavioral support, ruling out other medical contributors, or considering tirzepatide.

Does Wegovy work faster on a low-carb diet? Possibly. Low-carb diets produce 2 to 4 lbs of water-weight loss in the first week, which can make Wegovy appear to work faster. The fat-loss effect over 16+ weeks is similar across diet patterns as long as protein intake is adequate.

How long do Wegovy side effects last? Most GI side effects (nausea, constipation, reflux) are worst in the first 1 to 2 weeks of each dose level. They typically improve within 7 to 14 days. Some patients have persistent mild symptoms throughout treatment. Severe side effects warrant provider review.

Will Wegovy keep working after the first 6 months? For most patients, weight loss continues through about 12 months and then plateaus. Plateau is normal and represents a new equilibrium rather than failure. Stopping Wegovy at the plateau typically results in weight regain over the following 12 months unless lifestyle changes are sustained.

Does Wegovy work the same as Ozempic? Both contain semaglutide. Wegovy is dosed at 2.4 mg weekly and approved for obesity. Ozempic is dosed at 0.5 to 2 mg weekly and approved for type 2 diabetes. At equivalent doses they work the same way. The 2.4 mg Wegovy dose produces more weight loss than the standard 1 mg Ozempic dose.

Should I take Wegovy on the same day each week? Yes. Once-weekly dosing means roughly the same day each week. The label allows up to 2 days early or late if you need to shift the schedule. Try to keep injections consistent to maintain steady drug levels.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325:1403-1413.
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
5. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-2091.
6. Wegovy (semaglutide injection) prescribing information. Novo Nordisk; revised 2024.
7. Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Cell Metab. 2024;36:1-12.
8. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
9. Lingvay I, Hansen T, Macura S, et al. Superior weight loss with once-weekly semaglutide vs daily liraglutide. N Engl J Med. 2022;387:514-526.
10. American Association of Clinical Endocrinology Clinical Practice Guideline for the Care of Persons with Obesity. AACE; 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.